Sven Wegner

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Rheumatoid Arthritis

Atopic Dermatitis

Top Venues

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy 14 (3) (2024)
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy 14 (3) (2024)
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy 14 (3) (2024)
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy (2024)
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy 14 (3) (2024)
Alexander Egeberg, Curdin Conrad, Patricia Gorecki, Sven Wegner, Jozefien Buyze, Lorenzo Acciarri, Diamant Thaҫi
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and therapy 14 (3) (2024)